AbbVie Competitors and Similar CompaniesClear all
Astellas Pharma's competitors and similar companies include Gilead Sciences, Immunomedics, Sanofi, Amgen, Bristol Myers Squibb, Abbott, Merck Group, GSK, Novartis, Roche and Johnson & Johnson.
 Astellas Pharma Astellas Pharma (アステラス製薬株式会社) is a pharmaceutical company focused on the development of drugs and medical solutions. |  Gilead Sciences Gilead Sciences is a research-based biopharmaceutical company focused on the discovery, development, and commercialization of medicines. |  Immunomedics Immunomedics is a developer of monoclonal antibody-based products for the targeted treatment of cancer. |  Sanofi Sanofi is a healthcare company engaged in the research, development, manufacture, and marketing of therapeutic solutions. |  Amgen Amgen (formerly known as Applied Molecular Genetics) is a biotechnology company that discovers, develops, manufactures, and delivers human therapeutics. |  Bristol Myers Squibb Bristol-Myers Squibb (BMS) is a company engaged in the discovery, development, licensing, manufacturing, marketing, and distribution of biopharmaceutical products. |  Abbott Abbott Laboratories is a company that specializes in the discovery, development, manufacture, and sale of healthcare products. |  GSK GSK (GlaxoSmithKline) is a science-led healthcare company that researches, develops, and manufactures pharmaceutical medicines, vaccines, and consumer healthcare products. |  Novartis Novartis is a company that researches, develops, manufactures, and markets healthcare products. |  Johnson & Johnson Johnson & Johnson (J&J) is a company that engages in the research and development, manufacture, and sale of a range of products in the healthcare field. | |||
Founding Date | Founding Date 1923 | Founding Date 1987 | Founding Date 1982 | Founding Date 1994 | Founding Date 1980 | Founding Date 1887 | Founding Date 1888 | Founding Date 1668 | Founding Date 2000 | Founding Date 1996 | Founding Date 1896 | Founding Date 1886 |
Type | Type Public | Type Public | Type Subsidiary | Type Public | Type Public | Type Public | Type Public | Type Public | Type Public | Type Public | Type Public | Type Public |
Tags | ||||||||||||
Locations | Locations Tokyo, JP HQ Macquarie Park, AU Wien, AT Vilvoorde, BE São Paulo, BR Markham, CA Beijing, CN see more | Locations Foster City, US HQ Buenos Aires, AR Melbourne, AU Wien, AT Machelen, BE São Paulo, BR Edmonton, CA see more | Locations Morris Plains, US HQ | Locations Paris, FR HQ Hydra, DZ Buenos Aires, AR Macquarie Park, AU Melbourne, AU Virginia, AU Wien, AT see more | Locations Thousand Oaks, US HQ Hydra, DZ Vicente López, AR Sydney, AU Wien, AT Diegem, BE Santo Amaro, BR see more | Locations Princeton, US HQ Mulgrave, AU Pinewood, AU Wien, AT Braine L'alleud, BE Bruxelles, BE São Paulo, BR see more | Locations Abbott Park, US HQ Tiranë, AL Buenos Aires, AR Yerevan, AM Doncaster, AU East Brisbane, AU Macquarie Park, AU see more | Locations Darmstadt, DE HQ Buenos Aires, AR Bayswater, AU Macquarie Park, AU Wien, AT Hoeilaart, BE Rio De Janeiro, BR see more | Locations London, GB HQ Boumerdes, DZ Buenos Aires, AR Abbotsford, AU Wien, AT Wavre, BE Rio De Janeiro, BR see more | Locations Basel, CH HQ Tirana, AL Buenos Aires, AR Macquarie Park, AU Kundl, AT Unterlangkampfen, AT Wien, AT see more | Locations New Brunswick, US HQ Buenos Aires, AR Sydney, AU Vienna, AT Minsk, BY Beerse, BE Sofia, BG see more | |
Employees | Employees 14,754 | Employees 18,0006% increase | Employees 8914% decrease | Employees 82,878 | Employees 25,200 | Employees 34,100 | Employees 114,000 | Employees 62,34615% decrease | Employees 68,629 | Employees 75,883 | Employees 103,249 | Employees 138,1005% increase |
Valuation ($) | Valuation ($) 20.8 b | Valuation ($) 110.5 b | Valuation ($) N/A | Valuation ($) 141.1 b | Valuation ($) 170.4 b | Valuation ($) 97.8 b | Valuation ($) 196.1 b | Valuation ($) 71.6 b | Valuation ($) 862.5 m | Valuation ($) N/A | Valuation ($) N/A | Valuation ($) 396.3 b |
Financial | ||||||||||||
Revenue (est.) | Revenue (est.) ¥2.1t (FY, 2026) | Revenue (est.) $29.4b (FY, 2025) | Revenue (est.) $295k (FY, 2019) | Revenue (est.) €45.4b (FY, 2025) | Revenue (est.) $36.8b (FY, 2025) | Revenue (est.) $48.2b (FY, 2025) | Revenue (est.) $44.3b (FY, 2025) | Revenue (est.) €21.1b (FY, 2025) | Revenue (est.) £32.7b (FY, 2025) | Revenue (est.) $56.7b (FY, 2025) | Revenue (est.) CHF61.5b (FY, 2025) | Revenue (est.) $94.2b (FY, 2025) |
Cost of goods | Cost of goods ¥213.8b (FY, 2026) | Cost of goods $6.2b (FY, 2025) | Cost of goods N/A | Cost of goods €11.6b (FY, 2025) | Cost of goods $12b (FY, 2025) | Cost of goods $13.9b (FY, 2025) | Cost of goods $19.3b (FY, 2025) | Cost of goods €6.5b (FY, 2025) | Cost of goods £5.6b (FY, 2025) | Cost of goods $8.4b (FY, 2025) | Cost of goods CHF13.1b (FY, 2025) | Cost of goods $30.3b (FY, 2025) |
Gross profit | Gross profit ¥2t (FY, 2026) | Gross profit $23.2b (FY, 2025) | Gross profit $295k (FY, 2019) | Gross profit €37.6b (FY, 2025) | Gross profit $24.7b (FY, 2025) | Gross profit $34.3b (FY, 2025) | Gross profit $25b (FY, 2025) | Gross profit €15b (FY, 2025) | Gross profit £28.5b (FY, 2025) | Gross profit $49.8b (FY, 2025) | Gross profit CHF50.5b (FY, 2025) | Gross profit $63.9b (FY, 2025) |
Net income | Net income ¥291.6b (FY, 2026) | Net income $8.5b (FY, 2025) | Net income ($357.3m) (FY, 2019) | Net income €8b (FY, 2025) | Net income $7.7b (FY, 2025) | Net income $7.1b (FY, 2025) | Net income $6.5b (FY, 2025) | Net income €2.6b (FY, 2025) | Net income £6.3b (FY, 2025) | Net income $14b (FY, 2025) | Net income CHF13.8b (FY, 2025) | Net income $26.8b (FY, 2025) |
Operating ⚠ | ||||||||||||
Countries | Countries N/A | Countries 35 (FY, 2021) | Countries N/A | Countries N/A | Countries 100 (FY, 2020) | Countries N/A | Countries N/A | Countries 66 (FY, 2021) | Countries 92 (FY, 2021) | Countries N/A | Countries N/A | Countries N/A |
Patents (US) | Patents (US) N/A | Patents (US) N/A | Patents (US) 405 (Sep, 2022) | Patents (US) N/A | Patents (US) 31 (FY, 2020) | Patents (US) N/A | Patents (US) N/A | Patents (US) N/A | Patents (US) N/A | Patents (US) N/A | Patents (US) N/A | Patents (US) N/A |
Patients | Patients N/A | Patients N/A | Patients N/A | Patients N/A | Patients N/A | Patients N/A | Patients N/A | Patients N/A | Patients N/A | Patients 10 m (FY, 2022) | Patients 22.8 m (FY, 2023) | Patients N/A |
Phase I Trials Products | Phase I Trials Products N/A | Phase I Trials Products N/A | Phase I Trials Products N/A | Phase I Trials Products N/A | Phase I Trials Products 20 (FY, 2020) | Phase I Trials Products N/A | Phase I Trials Products N/A | Phase I Trials Products N/A | Phase I Trials Products 16 (FY, 2021) | Phase I Trials Products N/A | Phase I Trials Products N/A | Phase I Trials Products N/A |
Phase I Trials Products (Immunology) | Phase I Trials Products (Immunology) 1 (Oct, 2020) | Phase I Trials Products (Immunology) N/A | Phase I Trials Products (Immunology) N/A | Phase I Trials Products (Immunology) N/A | Phase I Trials Products (Immunology) N/A | Phase I Trials Products (Immunology) 6 (FY, 2021) | Phase I Trials Products (Immunology) N/A | Phase I Trials Products (Immunology) N/A | Phase I Trials Products (Immunology) N/A | Phase I Trials Products (Immunology) N/A | Phase I Trials Products (Immunology) N/A | Phase I Trials Products (Immunology) N/A |
Phase I Trials Products (Oncology) | Phase I Trials Products (Oncology) 1 (FY, 2020) | Phase I Trials Products (Oncology) 7 (FY, 2019) | Phase I Trials Products (Oncology) N/A | Phase I Trials Products (Oncology) 9 (FY, 2021) | Phase I Trials Products (Oncology) N/A | Phase I Trials Products (Oncology) 20 (FY, 2021) | Phase I Trials Products (Oncology) N/A | Phase I Trials Products (Oncology) N/A | Phase I Trials Products (Oncology) N/A | Phase I Trials Products (Oncology) N/A | Phase I Trials Products (Oncology) N/A | Phase I Trials Products (Oncology) N/A |
Phase II Trials Products | Phase II Trials Products N/A | Phase II Trials Products N/A | Phase II Trials Products N/A | Phase II Trials Products N/A | Phase II Trials Products 5 (FY, 2020) | Phase II Trials Products N/A | Phase II Trials Products N/A | Phase II Trials Products N/A | Phase II Trials Products 6 (FY, 2021) | Phase II Trials Products N/A | Phase II Trials Products N/A | Phase II Trials Products N/A |
Phase II Trials Products (Immunology) | Phase II Trials Products (Immunology) 1 (Oct, 2020) | Phase II Trials Products (Immunology) N/A | Phase II Trials Products (Immunology) N/A | Phase II Trials Products (Immunology) N/A | Phase II Trials Products (Immunology) N/A | Phase II Trials Products (Immunology) 6 (FY, 2021) | Phase II Trials Products (Immunology) N/A | Phase II Trials Products (Immunology) N/A | Phase II Trials Products (Immunology) N/A | Phase II Trials Products (Immunology) N/A | Phase II Trials Products (Immunology) N/A | Phase II Trials Products (Immunology) N/A |
Phase II Trials Products (Oncology) | Phase II Trials Products (Oncology) 1 (FY, 2020) | Phase II Trials Products (Oncology) 1 (FY, 2021) | Phase II Trials Products (Oncology) N/A | Phase II Trials Products (Oncology) 12 (FY, 2021) | Phase II Trials Products (Oncology) N/A | Phase II Trials Products (Oncology) 15 (FY, 2021) | Phase II Trials Products (Oncology) N/A | Phase II Trials Products (Oncology) N/A | Phase II Trials Products (Oncology) N/A | Phase II Trials Products (Oncology) N/A | Phase II Trials Products (Oncology) N/A | Phase II Trials Products (Oncology) N/A |
Phase III Trials Products | Phase III Trials Products N/A | Phase III Trials Products 9 (FY, 2021) | Phase III Trials Products N/A | Phase III Trials Products N/A | Phase III Trials Products 11 (FY, 2020) | Phase III Trials Products N/A | Phase III Trials Products N/A | Phase III Trials Products N/A | Phase III Trials Products 11 (FY, 2021) | Phase III Trials Products 44 (FY, 2022) | Phase III Trials Products N/A | Phase III Trials Products N/A |
Phase III Trials Products (Immunology) | Phase III Trials Products (Immunology) 1 (Oct, 2020) | Phase III Trials Products (Immunology) N/A | Phase III Trials Products (Immunology) N/A | Phase III Trials Products (Immunology) N/A | Phase III Trials Products (Immunology) N/A | Phase III Trials Products (Immunology) 3 (FY, 2021) | Phase III Trials Products (Immunology) N/A | Phase III Trials Products (Immunology) N/A | Phase III Trials Products (Immunology) N/A | Phase III Trials Products (Immunology) N/A | Phase III Trials Products (Immunology) N/A | Phase III Trials Products (Immunology) N/A |
Phase III Trials Products (Oncology) | Phase III Trials Products (Oncology) 4 (Oct, 2020) | Phase III Trials Products (Oncology) 4 (FY, 2021) | Phase III Trials Products (Oncology) N/A | Phase III Trials Products (Oncology) N/A | Phase III Trials Products (Oncology) N/A | Phase III Trials Products (Oncology) 7 (FY, 2021) | Phase III Trials Products (Oncology) N/A | Phase III Trials Products (Oncology) N/A | Phase III Trials Products (Oncology) N/A | Phase III Trials Products (Oncology) 27 (FY, 2021) | Phase III Trials Products (Oncology) N/A | Phase III Trials Products (Oncology) N/A |
Products | Products N/A | Products 21 (FY, 2021) | Products N/A | Products N/A | Products N/A | Products N/A | Products N/A | Products 300 k (FY, 2021) | Products N/A | Products N/A | Products N/A | Products N/A |
Suppliers | Suppliers N/A | Suppliers N/A | Suppliers N/A | Suppliers 68 k (FY, 2019) | Suppliers N/A | Suppliers N/A | Suppliers N/A | Suppliers N/A | Suppliers 37.5 k (FY, 2021) | Suppliers N/A | Suppliers N/A | Suppliers N/A |
Funding | ||||||||||||
Total funding raised | Total funding raised N/A | Total funding raised N/A | Total funding raised $ 30m | Total funding raised $ 310m | Total funding raised N/A | Total funding raised $ 15.5m | Total funding raised N/A | Total funding raised $ 121m | Total funding raised N/A | Total funding raised $ 6.5m | Total funding raised $ 7.8b | Total funding raised N/A |
For sources of this data, please see the company profile
View Company Profiles
Gilead Sciences
HQ
Foster City, US
Employees
18,000↑ 6% increase
Gilead Sciences is a research-based biopharmaceutical company focused on the discovery, development, and commercialization of medicines.
View companyImmunomedics
HQ
Morris Plains, US
Immunomedics is a developer of monoclonal antibody-based products for the targeted treatment of cancer.
View companySanofi
HQ
Paris, FR
Employees
82,878
Sanofi is a healthcare company engaged in the research, development, manufacture, and marketing of therapeutic solutions.
View companyAmgen
HQ
Thousand Oaks, US
Employees
25,200
Amgen (formerly known as Applied Molecular Genetics) is a biotechnology company that discovers, develops, manufactures, and delivers human therapeutics.
View company